Company Profile

Thyreos Inc
Profile last edited on: 1/18/2023      CAGE: 8U0N5      UEI: GFGNCMZKKLF7

Business Identifier: Uroinvasive herpes viruses amendable to Thyreos R2 vaccine implementation.
Year Founded
2021
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2125 Transformation Drive Suite 1000
Lincoln, NE 68508
   (402) 480-5837
   N/A
   www.thyreosvaccines.com
Location: Single
Congr. District: 01
County: Lancaster

Public Profile

Developing herpesvirus vaccines and vaccine vectors for the animal health and human health markets, the vaccines developed by Thyreos Inc are based on a recombinant herpes virus platform that elicits robust immune responses without infecting the nervous system. Known for causing cold sores and genital sores, herpes simplex viruses are part of the herpesvirus family - a family that also includes varicella zoster virus -- the causative agent of chickenpox and shingles -- and many veterinary pathogens that share a unique property: an ability robustly to invade the nervous system and quietly to reside there lifelong. Periodic reactivation of the latent infection results in the contagious shedding of infectious virus, which is often associated with mild or sometimes severe disease.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 USDA $174,235
Project Title: The first non-neuroinvasive live-attenuated bovine herpesvirus type 1 vaccine
0 1 NIH $297,493
Project Title: An R2 non-neuroinvasive herpes simplex virus type 2 vaccine

Key People / Management

  Eric Zeece -- CEO

  Gregory Allan Smith

Company News

There are no news available.